United Therapeutics – TYVASO (treprostinil) INCREASE Study Data

Dr. Leigh Peterson, Ph.D., Vice President of Product Development at United Therapeutics discusses data published in the “New England Journal of Medicine” (Jan 2021) on the INCREASE study evaluating Tyvaso in pulmonary hypertension associated with interstitial lung disease (PH-ILD). The INCREASE study is the first to demonstrate a clear benefit in patients with PH-ILD, a life-threatening disease with no currently FDA-approved treatments.  She talks about what’s next for Tyvaso as they look to achieve FDA approval.

Leigh Peterson: In her role as Vice President, Product Development, Dr. Peterson is responsible for coordinating and managing all aspects of preclinical and clinical development of United Therapeutics’ products. Dr. Peterson joined United Therapeutics in 2008 as a Senior Clinical Research Scientist and was promoted to her current role as Vice President of Product Development in March 2017. Dr. Peterson received a BS in Biochemistry from the University of Wyoming, a PhD in Molecular Biology – Human Genetics from the University of Utah, and conducted postdoctoral research in Developmental Neurobiology at The Rockefeller University.